Surgical resection, when combined with chemotherapy, has been shown to significantly
improve the survival rate of patients with pancreatic ductal adenocarcinoma (PDAC) …

Pancreatic cancer is the third leading cause of cancer-related deaths in the United States.
Pancreatic ductal adenocarcinoma (PDA) is the most common (90%) and aggressive type of …

Pancreatic ductal adenocarcinoma (PDAC) constitutes one of the most aggressive
malignancies with a 5-year survival rate of< 7%. Due to growing incidence, late diagnosis …

The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than
6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In …

An improvement in pancreatic cancer treatment represents an urgent medical goal. Late
diagnosis and high intrinsic resistance to conventional chemotherapy has led to a dismal …

Pancreatic cancer is one of the most aggressive human cancer types with a five-year
survival less than 7%. Emerging evidence revealed that many genetic alterations in …

Simple Summary Epigenetic alterations contribute to the distinct biology of pancreatic ductal
adenocarcinoma (PDAC) and thus allow a better understanding of molecular mechanisms …

Pancreatic cancer (PC) is an aggressive disease characterized by high mortality. Diagnosis
at advanced stage, resistance, and recurrence are major hurdles for PC therapy and …

Accumulation of multiple genetic and/or epigenetic abnormalities is required for generation
and progression of cancers, and the survival of cancer cells might depend on addiction to …

Background: Pancreatic ductal adenocarcinoma (PDAC) remains a major challenge in
cancer medicine and is characterized by a 5-year survival rate of< 10%. Compelling …